2025-05-22-Jefferies-MRD_它们可能是什么_引入我们的详细市场模型_11页_973kb

MRD Market Analysis Summary

Market Overview

• Invasion and map the $20B addressable market for Solid Tumor Minimal Residual Disease (MRD).
• Natera (NTRA) is the current market leader with a forward valuation of 9x sales.
• The market is expected to grow at nearly 20% CAGR through exponential penetration.
• A detailed market model indicates $5.5B market value at 25% market penetration by 2034.

Key Drivers & Competition

• Recent Launches & Reimbursement: EXAS launched Oncodetect, DGX launched Haystack MRD, LH launched Plasma Detect.
• Guardant Health (GH) recently achieved surveillance reimbursement for CRC.
• Competition: NTRA faces pressure from EXAS, GH, Personalis/TEM, MYGN, NEO, Quest (DGX), LabCorp (LH).
• Test Performance: Sensitivity & specificity are the most crucial attributes, with Signatera having a strong reference standard due to extensive validation.

Analyst Take & Upgrades

• Jefferies revisits market assumptions due to NTRA's comments on future Signatera revenues.
• Reaffirms NTRA as market leader, despite potential share loss, if penetration ramps (+LSD%).
• GH (Reveal) expects modest share gain (from 2.5% to 4.3%) aided by surveillance reimbursement.
• EXAS remains top pick despite minimal MRD exposure, driven by strong Cologuard franchise.
• Valuations: NTRA (9x sales), EXAS/GH/LH (Buy ratings), MYGN (Underperform).

Risks & Caveats

• Broader adoption faces hurdles with guidelines (NCCN) and cost.
• Newer assays may struggle to gain market share due to less extensive validation than Signatera.
• Market is becoming increasingly competitive; late movers (MYGN, NEO) may need significant catch-up.

Investment Outlook

Let me know if you need further refinement or adjustment based on your specific requirements.